Sei Investments Co. Increases Holdings in Viridian Therapeutics, Inc. $VRDN

Sei Investments Co. lifted its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 117.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 65,777 shares of the company’s stock after acquiring an additional 35,459 shares during the period. Sei Investments Co. owned 0.06% of Viridian Therapeutics worth $1,287,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in VRDN. MetLife Investment Management LLC lifted its stake in shares of Viridian Therapeutics by 0.8% in the 4th quarter. MetLife Investment Management LLC now owns 43,985 shares of the company’s stock valued at $1,369,000 after purchasing an additional 356 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Viridian Therapeutics by 0.3% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 139,360 shares of the company’s stock valued at $4,337,000 after buying an additional 380 shares during the period. US Bancorp DE lifted its position in Viridian Therapeutics by 23.2% in the third quarter. US Bancorp DE now owns 2,457 shares of the company’s stock worth $53,000 after buying an additional 463 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in Viridian Therapeutics by 0.3% during the first quarter. Bank of New York Mellon Corp now owns 216,525 shares of the company’s stock worth $4,235,000 after buying an additional 659 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Viridian Therapeutics by 1.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,276 shares of the company’s stock valued at $669,000 after acquiring an additional 876 shares during the last quarter.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on VRDN shares. Weiss Ratings cut shares of Viridian Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 30th. Wells Fargo & Company raised shares of Viridian Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $20.00 to $31.00 in a research note on Monday, June 29th. Needham & Company LLC reaffirmed a “buy” rating and set a $32.00 target price on shares of Viridian Therapeutics in a research note on Monday, June 29th. Truist Financial increased their price target on Viridian Therapeutics from $38.00 to $39.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Finally, Stifel Nicolaus set a $39.00 price objective on Viridian Therapeutics in a report on Wednesday, May 13th. Thirteen equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $38.93.

Viridian Therapeutics Stock Down 0.4%

Shares of NASDAQ:VRDN opened at $22.97 on Wednesday. The business’s 50 day moving average is $18.65 and its 200 day moving average is $21.45. The stock has a market cap of $2.60 billion, a P/E ratio of -6.82 and a beta of 0.91. Viridian Therapeutics, Inc. has a 52-week low of $13.18 and a 52-week high of $34.29. The company has a quick ratio of 15.15, a current ratio of 15.15 and a debt-to-equity ratio of 0.10.

Viridian Therapeutics (NASDAQ:VRDN) last issued its earnings results on Thursday, August 6th. The company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.03) by ($0.02). Viridian Therapeutics had a negative net margin of 505.86% and a negative return on equity of 76.65%. The firm had revenue of $0.28 million for the quarter, compared to the consensus estimate of $0.06 million. Sell-side analysts predict that Viridian Therapeutics, Inc. will post -4.09 EPS for the current year.

About Viridian Therapeutics

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.